SG11201909856XA - Mesenchymal lineage precursor or stem cells with enhanced immunosuppression - Google Patents

Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Info

Publication number
SG11201909856XA
SG11201909856XA SG11201909856XA SG11201909856XA SG 11201909856X A SG11201909856X A SG 11201909856XA SG 11201909856X A SG11201909856X A SG 11201909856XA SG 11201909856X A SG11201909856X A SG 11201909856XA
Authority
SG
Singapore
Prior art keywords
international
stem cells
mesenchymal lineage
lineage precursor
pct
Prior art date
Application number
Other languages
English (en)
Inventor
Silviu Itescu
Paul Simmons
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901633A external-priority patent/AU2017901633A0/en
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of SG11201909856XA publication Critical patent/SG11201909856XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201909856X 2017-05-04 2018-05-04 Mesenchymal lineage precursor or stem cells with enhanced immunosuppression SG11201909856XA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2017901633A AU2017901633A0 (en) 2017-05-04 Potency assay for immunosuppression
AU2017901636A AU2017901636A0 (en) 2017-05-04 Method for treating Graft versus Host Disease (GVHD)
AU2018900551A AU2018900551A0 (en) 2018-02-21 Potency assay for immunosuppression II
PCT/EP2018/061503 WO2018202853A1 (en) 2017-05-04 2018-05-04 Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Publications (1)

Publication Number Publication Date
SG11201909856XA true SG11201909856XA (en) 2019-11-28

Family

ID=62222586

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909856X SG11201909856XA (en) 2017-05-04 2018-05-04 Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Country Status (10)

Country Link
US (1) US20200325450A1 (https=)
EP (2) EP4137562A1 (https=)
JP (3) JP7398959B2 (https=)
KR (2) KR102660506B1 (https=)
CN (1) CN110753751A (https=)
AU (2) AU2018262788B2 (https=)
BR (1) BR112019022901A2 (https=)
CA (1) CA3062112A1 (https=)
SG (1) SG11201909856XA (https=)
WO (1) WO2018202853A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SI2785359T1 (sl) 2011-11-30 2018-11-30 Astellas Institute For Regenerative Medicine Mezenhimske stromalne celice in uporabe povezane z njimi
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
HK1208054A1 (en) 2012-07-12 2016-02-19 爱姆斯坦生物技术公司 Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
SG11201909856XA (en) * 2017-05-04 2019-11-28 Mesoblast Int Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
KR20220143092A (ko) * 2020-02-19 2022-10-24 메조블라스트 인터내셔널 에스에이알엘 만성 이식편 대 숙주 질환의 치료 방법
JP7793284B2 (ja) * 2020-03-02 2026-01-05 株式会社ガイアバイオメディシン 高活性ｎｋ細胞の処理方法
JP2023530098A (ja) * 2020-06-11 2023-07-13 メゾブラスト・インターナショナル・エスアーエールエル 間葉系前駆細胞又は幹細胞の３ｄ培養
AU2021323475A1 (en) * 2020-08-10 2023-04-13 Mesoblast International Sarl A composition comprising mesenchymal precursor or stem cells and their use
CN112444479B (zh) * 2021-02-01 2021-05-07 宁波大学 基于并行处理技术的单细胞质谱分析系统及方法
CN113881707B (zh) * 2021-10-25 2023-07-14 中国人民解放军军事科学院军事医学研究院 调控脐带间充质干细胞免疫抑制作用的产品、方法及用途
US20250032552A1 (en) * 2021-12-23 2025-01-30 Mesoblast International Sárl Method of treating severe graft versus host disease
CA3260880A1 (en) * 2022-07-05 2024-01-11 Mesoblast International Sarl CRYOPROVERTED INTERMEDIATE AND BIOLOGICAL ACTIVITY TEST FOR IT
KR20250049337A (ko) 2022-08-09 2025-04-11 엑손모빌 케미칼 패턴츠 인코포레이티드 디페닐실란 가교 c1 대칭 촉매의 제조 방법 및 이로부터 제조된 중합체
WO2024168161A1 (en) * 2023-02-08 2024-08-15 Mesoblast International Sarl Potency assay and manufacturing method
WO2025196663A1 (en) * 2024-03-19 2025-09-25 Mesoblast International Sarl Potency assay and manufacturing method ii
CN118147232B (zh) * 2024-05-09 2024-07-19 中国人民解放军联勤保障部队第九二〇医院 一种过表达tps1间充质干细胞的构建方法及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU8200191A (en) 1990-07-09 1992-02-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
WO1994026877A1 (en) 1993-05-17 1994-11-24 The Regents Of The University Of California Ribozyme gene therapy for hiv infection and aids
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
US6566051B1 (en) 1999-01-15 2003-05-20 Medtox Scientific, Inc. Lateral flow test strip
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US7205159B2 (en) 2001-08-20 2007-04-17 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
WO2004046729A2 (en) 2002-11-21 2004-06-03 The University Of Leicester Bodily fluid markers of tissue hypoxia
CN101248171B (zh) 2005-04-12 2015-11-25 迈索布拉斯特股份有限公司 通过组织非特异性碱性磷酸酶分离成人多潜能细胞
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
KR101891260B1 (ko) * 2010-07-02 2018-08-24 메소블라스트, 아이엔씨. T-세포 매개된 면역 질환의 치료
US20120087868A1 (en) * 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
KR20150016117A (ko) * 2013-07-30 2015-02-11 코아스템(주) 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물
SG11201607925SA (en) * 2014-04-07 2016-10-28 Mesoblast Internat Sarl Improved stem cell composition
EP3236977B1 (en) * 2014-12-23 2023-06-21 Mesoblast International Sàrl Method for treating heart failure
SG11201909856XA (en) 2017-05-04 2019-11-28 Mesoblast Int Sarl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression

Also Published As

Publication number Publication date
JP2020518260A (ja) 2020-06-25
WO2018202853A1 (en) 2018-11-08
EP4137562A1 (en) 2023-02-22
KR102884611B1 (ko) 2025-11-12
KR102660506B1 (ko) 2024-04-25
EP3619294A1 (en) 2020-03-11
US20200325450A1 (en) 2020-10-15
AU2018262788B2 (en) 2024-08-15
KR20200003044A (ko) 2020-01-08
JP2026034487A (ja) 2026-02-27
JP7787130B2 (ja) 2025-12-16
JP2023174760A (ja) 2023-12-08
JP7398959B2 (ja) 2023-12-15
BR112019022901A2 (pt) 2020-05-19
CA3062112A1 (en) 2018-11-08
AU2024227344A1 (en) 2024-10-31
CN110753751A (zh) 2020-02-04
KR20240056790A (ko) 2024-04-30
AU2018262788A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
SG11201909856XA (en) Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
SG11201909949XA (en) Targeted immunotolerance
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201909777YA (en) Modulatory polynucleotides
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201811432WA (en) Rna for cancer therapy
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201806639VA (en) New streptococcal proteases
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201811221XA (en) Imidazo[1,2-a]pyridine derivatives, methods for preparing the same and use thereof
SG11201808964PA (en) Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201909520VA (en) Rna for treatment of autoimmune diseases